Rituximab for the second-and third-line therapy of idiopathic membranous nephropathy: A prospective single center study using a new treatment strategy

Clinical Nephrology

Volumn 80, Issue 2, 2013, Pages 105-113

  Busch, Martin ^a   Rüster, Christiane ^a   Schinköthe, Claudia ^a   Gerth, Jens ^b   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Heinrich Braun Hospital   (Germany)

Author keywords

Line treatment; Membranous nephropathy; Nephrotic syndrome; Rituximab; Second

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOOP DIURETIC AGENT; PARACETAMOL; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG INFUSION; DUODENUM DISEASE; FEMALE; FEMUR NECK FRACTURE; GLOMERULOSCLEROSIS; GLUCOSE TOLERANCE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OSTEOPENIA; PNEUMOCYSTOSIS; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; REMISSION; SIDE EFFECT; SKIN DISEASE; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84881513360     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107912     Document Type: Article

References (14)

1. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998; 9: 444-450.
2. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59: 1484-1490.
3. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117-125.
4. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010; 5: 2188-2198.
5. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012; 23: 1416-1425.
6. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007; 2: 932-937.
7. Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011; 33: 461-468.
8. http://www.kdigo.org/clinical_practice_guidelines/Glomerulonephritis.php.
9. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol. 2003; 14: 3217-3232.
10. Michel PA, Dahan K, Ancel PY, Plaisier E, Mojaat R, De Seigneux S, Daugas E, Matignon M, Mesnard L, Karras A, François H, Pardon A, Caudwell V, Debiec H, Ronco P. Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra. 2011; 1: 251-261.
11. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, Gomez MR, Montoro B, Camps J. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009; 4: 1083-1088.
12. Busch M, Gerth J, Ott U, Schip A, Haufe CC, Gröne HJ, Wolf G. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?]. Med Klin (Munich). 2008; 103: 519-524.
13. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol. 2006; 1: 738-748.
14. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA. An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011; 26: 2526-2532.